Literature DB >> 21769632

First isolation of Candida dubliniensis from oral cavities of dermatological patients in Nanjing, China.

Yi P Ge1, Guo X He, Tong Lin, Gui X Lu, Yong N Shen, Wei D Liu.   

Abstract

Candida dubliniensis is an emerging pathogen capable of causing both superficial and systemic infections. Although C. dubliniensis and C. albicans are phenotypically similar, the two species differ in terms of epidemiology and the ability to rapidly develop resistance to fluconazole. C. dubliniensis is primarily associated with oral candidiasis of human immunodeficiency virus (HIV)-infected individuals. In this study, we describe the first recovery of C. dubliniensis from oral cavities of non-HIV-infected patients with dermatological diseases in Nanjing, China. The isolates were phenotypically characterized as C. dubliniensis by their production of brown rough colonies and chlamydospores on tobacco agar and their inability to grow on hypertonic Sabouraud dextrose agar or to assimilate xylose or α-methyl-D-glycoside. The species identification was subsequently confirmed by amplification and sequencing of the internal transcribed spacer region (ITS). Three C. dubliniensis isolates out of 128 (2.3%) presumptive C. albicans/C. dubliniensis ones were finally identified. Further sequence analysis separated the three isolates into two of the four reported ITS genotypes. Antifungal susceptibility testing showed that they were susceptible to fluconazole, itraconazole, voriconazole, micafungin, and amphotericin B. This study adds to the accumulating evidence that C. dubliniensis is widely distributed in non-HIV-infected populations worldwide.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21769632     DOI: 10.1007/s11046-011-9447-1

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  29 in total

1.  Retrospective identification and characterization of Candida dubliniensis isolates among Candida albicans clinical laboratory isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected individuals.

Authors:  M A Jabra-Rizk; W A Falkler; W G Merz; A A Baqui; J I Kelley; T F Meiller
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

2.  Identification of four distinct genotypes of Candida dubliniensis and detection of microevolution in vitro and in vivo.

Authors:  Sarah F Gee; Sophie Joly; David R Soll; Jacques F G M Meis; Paul E Verweij; Itzhack Polacheck; Derek J Sullivan; David C Coleman
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

3.  New PCR primer pairs specific for Candida dubliniensis and detection of the fungi from the Candida albicans clinical isolates in Japan.

Authors:  M Tamura; K Watanabe; T Imai; Y Mikami; K Nishimura
Journal:  Clin Lab       Date:  2000       Impact factor: 1.138

4.  Recovery of Candida dubliniensis from non-human immunodeficiency virus-infected patients in Israel.

Authors:  I Polacheck; J Strahilevitz; D Sullivan; S Donnelly; I F Salkin; D C Coleman
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

5.  Prevalence of Candida dubliniensis isolates in a yeast stock collection.

Authors:  F C Odds; L Van Nuffel; G Dams
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

6.  Identification of Candida dubliniensis based on temperature and utilization of xylose and alpha-methyl-D-glucoside as determined with the API 20C AUX and vitek YBC systems.

Authors:  A C Gales; M A Pfaller; A K Houston; S Joly; D J Sullivan; D C Coleman; D R Soll
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

7.  Epidemiology of oropharyngeal Candida colonization and infection in patients receiving radiation for head and neck cancer.

Authors:  S W Redding; R C Zellars; W R Kirkpatrick; R K McAtee; M A Caceres; A W Fothergill; J L Lopez-Ribot; C W Bailey; M G Rinaldi; T F Patterson
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

8.  Candida dubliniensis candidemia in patients with chemotherapy-induced neutropenia and bone marrow transplantation.

Authors:  J F Meis; M Ruhnke; B E De Pauw; F C Odds; W Siegert; P E Verweij
Journal:  Emerg Infect Dis       Date:  1999 Jan-Feb       Impact factor: 6.883

9.  Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals.

Authors:  D J Sullivan; T J Westerneng; K A Haynes; D E Bennett; D C Coleman
Journal:  Microbiology       Date:  1995-07       Impact factor: 2.777

10.  Tobacco agar, a new medium for differentiating Candida dubliniensis from Candida albicans.

Authors:  Zia U Khan; Suhail Ahmad; Eiman Mokaddas; Rachel Chandy
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

View more
  4 in total

1.  Species Distribution, Virulence Factors, and Antifungal Susceptibility Among Candida parapsilosis Complex Isolates Recovered from Clinical Specimens.

Authors:  Beatriz Virgínia da Silva; Larissa Beatriz Silva; Diego Batista Carneiro de Oliveira; Paulo Roberto da Silva; Kennio Ferreira-Paim; Leonardo Euripides Andrade-Silva; Mario León Silva-Vergara; Anderson Assunção Andrade
Journal:  Mycopathologia       Date:  2015-07-03       Impact factor: 2.574

2.  Methods of Candida dubliniensis identification and its occurrence in human clinical material.

Authors:  Martina Mahelová; Filip Růžička
Journal:  Folia Microbiol (Praha)       Date:  2017-05-17       Impact factor: 2.099

3.  Patterns of human oral yeast species distribution on Hainan Island in China.

Authors:  Huamin Wang; Jianping Xu; Hong Guo; Jinyan Wu; Guohui Yi; Hua Pei; Lina Niu; Yi Li
Journal:  Mycopathologia       Date:  2013-10-02       Impact factor: 2.574

4.  Isolation of Candida spp. from denture-related stomatitis in Pará, Brazil.

Authors:  Lurdete Maria Rocha Gauch; Simone Soares Pedrosa; Fabíola Silveira-Gomes; Renata Antunes Esteves; Silvia Helena Marques-da-Silva
Journal:  Braz J Microbiol       Date:  2017-07-29       Impact factor: 2.476

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.